Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.43 |
| ▸ | DPP4 | P27487 | 4/20 | 0.43 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7894841 | 0.93 | KCNH2 (0.50) | KCNH2TMEM97SIGMAR1HRH3DPP8 | |
| SCHEMBL10057635 | 0.85 | KCNH2 (0.59) | KCNH2TMEM97SIGMAR1DPP8DPP9 | |
| SCHEMBL2632967 | 0.84 | KCNH2 (0.52) | KCNH2TMEM97SIGMAR1HRH3DPP8 | |
| SCHEMBL12382091 | 0.82 | KCNH2 (0.47) | KCNH2TMEM97SIGMAR1HRH3DPP8 | |
| SCHEMBL10263983 | 0.81 | HRH3 (0.49) | KCNH2HRH3DPP8DPP9DPP7 | |
| SCHEMBL26575966 | 0.80 | HRH3 (0.42) | HRH3ASIC3HTR2ASLC6A4HTR2B | |
| SCHEMBL4327480 | 0.79 | DRD1 (0.50) | HRH3ASIC3DRD2DRD3 | |
| SCHEMBL22322073 | 0.79 | HRH3 (0.48) | HRH3DPP8DPP9DPP7ASIC3 | |
| SCHEMBL10199349 | 0.79 | HRH3 (0.48) | HRH3ASIC3HTR2A | |
| SCHEMBL1950813 | 0.79 | HRH3 (0.48) | HRH3ASIC3HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8148404-B2 | Modulators of CB1 receptors | 7TM PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| US-20100144701-A1 | Modulators of CB1 Receptors | 7TM PHARMA A/S (DK) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144701-A1 | Modulators of CB1 Receptors | CNR1, CNR2, GPR6 | KCNH2 1148/4885TMEM97 767/4885SIGMAR1 259/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | KCNH2 409/4885TMEM97 328/4885SIGMAR1 152/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | KCNH2 4811/4885TMEM97 3680/4885SIGMAR1 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.